Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 612 across all filing types
Latest filing 2020-11-05 Regulatory Filings
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Alligator Bioscience presents the CD40 antibody mitazalimab at the World Immunotherapy Congress 2020
Regulatory Filings Classification · 1% confidence The document is a press release from Alligator Bioscience announcing the presentation of data for its drug mitazalimab at a scientific congress (World Immunotherapy Congress 2020). It details preclinical and clinical data, management commentary, and future plans (submission of CTA for a Phase Ib/II study). This type of announcement, focusing on scientific/clinical updates and investor relations communication outside of mandatory financial reporting periods (like 10-K or ER), fits best under the general 'Regulatory Filings' category (RNS) as it is a broad regulatory/investor communication, or potentially 'Investor Presentation' (IP) if it were the presentation itself, but since it is the *announcement* of the presentation, RNS is the most appropriate general category for non-standard announcements. Given the options, RNS serves as the best fit for a general corporate/scientific update press release that isn't a core financial report (10-K, ER, IR) or a specific management/dividend notice.
2020-11-05 English
Förväntat terapeutiska dosnivåer uppnådda i fas I-studie med ATOR-1017
Regulatory Filings Classification · 1% confidence The document is a press release from Alligator Bioscience dated October 27, 2020, announcing positive safety data and dose escalation in their ongoing Phase I clinical study for the drug candidate ATOR-1017. It discusses clinical trial progress, dose levels achieved, expected timelines for final results and the start of Phase Ib/II studies, and includes standard boilerplate information about the company and contact details. This type of announcement, focusing on clinical trial updates and future development plans, is characteristic of an Investor Presentation (IP) or a general press release about R&D progress. Since it is a specific update on development progress rather than a general earnings release (ER) or a formal regulatory filing like a 10-K, and it provides detailed context on the drug development, 'Investor Presentation' (IP) is the closest fit for detailed R&D updates, although 'Regulatory Filings' (RNS) is also plausible for general announcements. Given the detailed nature of the clinical update and the forward-looking statements regarding future studies, IP is slightly more appropriate than the general RNS fallback, as it serves to inform investors about the pipeline status. However, since it is a short press release announcing results rather than a full presentation deck, and it explicitly mentions being subject to EU Market Abuse Regulation disclosure, it functions primarily as a regulatory announcement. In the context of the provided definitions, it is a specific update that doesn't fit perfectly into ER, IR, or AR. It is most similar to an announcement of R&D progress, which often accompanies an IP, but the document itself is a news release. Given the options, and recognizing it as a specific, time-sensitive corporate update, RNS (Regulatory Filings/General Announcement) is the safest classification, although IP captures the content focus better. I will lean towards RNS as it is a formal announcement of material information.
2020-10-27 Swedish
Predicted therapeutic range dose levels reached in ATOR-1017 Phase I
Regulatory Filings Classification · 1% confidence The document is a press release dated October 27, 2020, from Alligator Bioscience announcing positive interim safety data from a clinical Phase I study for their drug candidate ATOR-1017. It details dose levels reached, observed adverse events, and quotes the CEO regarding milestones and future plans (Phase II study). This content structure—announcing key operational/clinical updates and financial/business highlights outside of mandated periodic financial reports (like 10-K or IR)—is characteristic of an Earnings Release (ER) or a general business update. Since it focuses on clinical trial progress and operational milestones rather than explicitly reporting quarterly/periodical financial results (which would typically be an ER), and it is not a transcript, presentation, or formal regulatory filing like a DIRS or DIV, it best fits the general category of a business update. Given the options, 'ER' (Earnings Release) is often used broadly for significant periodic operational announcements, but 'RNS' (Regulatory Filings) serves as the best fallback for specific operational news that doesn't fit the other precise categories. However, announcements of clinical trial progress are often categorized as Earnings Releases or Investor Presentations. Since this is a short press release format announcing a key operational milestone (reaching dose levels), it aligns closely with the nature of an Earnings Release (ER) which often includes operational highlights alongside any financial data, or an Investor Presentation (IP) if it were a slide deck. Given the brevity and press release format announcing a significant operational milestone, and lacking the detailed financial tables of an IR, ER is a strong candidate, but RNS is the safest fallback for non-standard operational news. Reviewing the definitions, this is a specific operational update, not a general regulatory filing (RNS) or a formal presentation (IP). It is most similar to an Earnings Release (ER) which often contains operational updates, or potentially a Capital/Financing Update (CAP) if the trial progress directly impacts financing needs, but it's primarily clinical news. Since it's a press release announcing a key operational milestone, and it's not a formal financial report, I will classify it as a general Regulatory Filing (RNS) as it is a mandatory disclosure under EU Market Abuse Regulation, which doesn't fit the other specific categories well.
2020-10-27 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Q3 Delårsrapport januari-september 2020' (Q3 Interim Report January-September 2020) for Alligator Bioscience AB. It contains comprehensive financial statements, management commentary, key performance indicators, and operational updates for the third quarter. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-10-22 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 1% confidence The document is explicitly titled 'Q3 Interim report January-September 2020' and contains comprehensive financial statements, including income statements, cash flow data, and balance sheet metrics for the specified period. It provides detailed management commentary on clinical trials and operational performance, confirming it is a substantive financial report rather than a mere announcement or certification. 9M 2020
2020-10-22 English
Alligator Bioscience focuses on ATOR-1017 and mitazalimab
Regulatory Filings Classification · 1% confidence The document text explicitly mentions the release of the "Q3 interim report" on October 22, 2020, and immediately announces a conference call to discuss this report. The text itself is a short announcement (2990 characters) detailing strategic focus changes and referencing the attached or simultaneously released Q3 report. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement that references the publication of a report (like an interim report) is classified as a Report Publication Announcement (RPA), rather than the comprehensive report itself (which would be classified as IR).
2020-10-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.